MedTrace Logo

Clinical Trial Comparing the Efficacy and Safety of DA-3803 and Ovidrel

NCT01718119 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2013-08-13

No results posted yet for this study

Summary

The purpose of this study is to compare the efficacy and safety of DA-3803(r-hCG) and Ovidrel for inducting final follicular maturation and early luteinization in women undergoing ovulation induction for assisted reproduction treatment

Conditions

  • Hyperovulation Induction for Assisted Reproduction Treatment

Interventions

DRUG

r-hCG

r-hCG(250mcg) injection subcutaneously

Sponsors & Collaborators

  • Dong-A Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • TaeGi Yoon, MD · Cha Medical school Gangnam-Cha hospital

  • DongHee Choi, MD · Cha Medical school Boondang-Cha hospital

  • MiKyoung Goong, MD · Kwandong university medical school Cheil hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
38 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2013-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01718119 on ClinicalTrials.gov